With a total CSR spend of INR 35.9 crore, Mankind Pharma reaffirms its commitment to uplifting communities and contributing to a more equitable and prosperous society.
NEW DELHI (India CSR): Mankind Pharma Limited, a prominent name in the healthcare sector, has announced a total Corporate Social Responsibility (CSR) expenditure of INR 35.9 crore for the financial year 2023-24. The company’s CSR initiatives align with its vision of creating sustainable and inclusive development, benefiting underserved sections of society.
In the financial year 2022-23, Mankind Pharma demonstrated an exceptional commitment to its Corporate Social Responsibility (CSR) by allocating Rs. 19.41 crores towards CSR obligations.
Major Focus Areas of CSR Initiatives
Mankind Pharma’s CSR activities for FY 2023-24 revolved around five key pillars:
- Health and Hygiene
- Over INR 2 crore invested in strengthening healthcare infrastructure, including construction and procurement of essential medical equipment.
- 110+ toilets constructed under the Individual Household Latrines (IHHL) initiative to improve sanitation.
- 10,000+ children benefited from school health programs implemented in 120 schools, providing health education and services.
- Health camps were organized to raise awareness about adolescent health issues and promote healthy habits.
- Educational Development
- INR 3.7 crore was allocated to enhance educational infrastructure, focusing on access to quality education for underserved communities.
- Support is provided to institutions such as Ashoka University through scholarships for meritorious students.
- Environmental Development
- Programs aimed at raising environmental awareness and promoting sustainable practices in communities.
- Livelihood Generation
- Initiatives supporting entrepreneurship and skill development, contributing to economic self-reliance.
- Knowledge Institution Support
- Partnerships with academic and research institutions to promote community development and innovation.
Detailed CSR Governance
Mankind Pharma follows a structured and transparent approach to its CSR efforts, guided by a governance framework that ensures effective execution and impact assessment.
Key Governance Highlights:
- CSR Committee Composition:
- Ramesh Juneja – Chairman (Whole-time Director).
- Rajeev Juneja – Member (Managing Director).
- Surendra Lunia – Member (Independent Director).
- CSR Committee Meetings: 2 held during FY 2023-24, with 100% attendance by all members.
Impact Assessment of CSR Projects
Independent agencies assessed the impact of Mankind’s CSR initiatives, including contributions to:
- Tata Memorial Cancer Hospital.
- JC Juneja Hospital.
- VSPM Academy.
- Vanvasi Raksha Parivar Foundation.
These assessments confirmed the alignment of initiatives with the company’s mission to improve community well-being. The detailed reports are available on the company’s website.
Financial Overview
Key CSR Financial Figures for FY 2023-24:
- Average Net Profit as per Section 135: INR 1,65,364.03 lakhs.
- Mandatory CSR Spending: INR 3,307.28 lakhs.
- Total CSR Spending: INR 3,257.20 lakhs.
- Administrative Overheads: INR 20.50 lakhs.
- Unspent CSR Amount: NIL.
Broader Impact
The company’s projects focus on addressing pressing societal challenges such as healthcare accessibility, quality education, environmental sustainability, and economic empowerment.
Also Read
Mankind Pharma Spends Rs. 20 Crore on CSR in FY 2022-23 I India CSR – Largest CSR Media
(India CSR)
